Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Moodys
Medtronic
Johnson and Johnson
AstraZeneca

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020865

See Plans and Pricing

« Back to Dashboard

NDA 020865 describes MAXALT-MLT, which is a drug marketed by Merck and is included in one NDA. It is available from one supplier. Additional details are available on the MAXALT-MLT profile page.

The generic ingredient in MAXALT-MLT is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.
Summary for 020865
Tradename:MAXALT-MLT
Applicant:Merck
Ingredient:rizatriptan benzoate
Patents:0
Pharmacology for NDA: 020865
Suppliers and Packaging for NDA: 020865
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865 NDA Merck Sharp & Dohme Corp. 0006-3800 0006-3800-18 6 CONTAINER in 1 CARTON (0006-3800-18) > 3 POUCH in 1 CONTAINER > 1 BLISTER PACK in 1 POUCH (0006-3800-01) > 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865 NDA Merck Sharp & Dohme Corp. 0006-3801 0006-3801-18 6 CONTAINER in 1 CARTON (0006-3801-18) > 3 POUCH in 1 CONTAINER > 1 BLISTER PACK in 1 POUCH (0006-3801-01) > 1 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK
Paragraph IV (Patent) Challenges for 020865
Tradename Dosage Ingredient NDA Submissiondate
MAXALT-MLT TABLET, ORALLY DISINTEGRATING;ORAL rizatriptan benzoate 020865 2006-02-17

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 5MG BASE
Approval Date:Jun 29, 1998TE:RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrengthEQ 10MG BASE
Approval Date:Jun 29, 1998TE:ABRLD:Yes

Expired US Patents for NDA 020865

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-002 Jun 29, 1998   Start Trial   Start Trial
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-001 Jun 29, 1998   Start Trial   Start Trial
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-001 Jun 29, 1998   Start Trial   Start Trial
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-002 Jun 29, 1998   Start Trial   Start Trial
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-002 Jun 29, 1998   Start Trial   Start Trial
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-002 Jun 29, 1998   Start Trial   Start Trial
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-001 Jun 29, 1998   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
McKesson
Dow
Medtronic
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.